KALA BIO, Inc. KALA
3.43 USD -0.40 (-10.44%)
Regular-session close
3.43 0.00 0.00%
After hours · Nov 17, 4:00 PM ET
3.42 Day range 3.70
0.139 52-week range 66.50
- YTD
- -87.66%
- 1 year
- -90.19%
News
newsfilecorp.com KALA BIO Announces Reverse Stock Split Common Stock Will Begin Trading on a Split-Adjusted Basis on November 16, 2026 Arlington, Massachusetts--(Newsfile Corp. - November 12, 2026) - KALA BIO, Inc. (NASDAQ: KALA) ("KALA BIO" or the…
newsfilecorp.com KALA BIO Provides CEO Update and Preliminary Third Quarter 2026 Financial Results New York, New York--(Newsfile Corp. - November 9, 2026) - KALA BIO, Inc. (NASDAQ: KALA) today announced preliminary unaudited financial results for the quarter ended September 30, 2026. Preliminary…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Curis (NASDAQ:CRIS) stock moved upwards by 83.5% to $1.31 during Wednesday's pre-market session. The company's market cap stands at $1.7 million. SCWorx (NASDAQ:WORX) stock increased by…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares…
defenseworld.net KALA BIO, Inc. (NASDAQ:KALA) Stock Short Interest Report for September KALA BIO, Inc. (NASDAQ: KALA - Get Free Report) was the target of a large growth in short interest in September. As of September 30th, there was short interest totaling 1,358,824 shares, a growth of…
defenseworld.net KALA BIO (NASDAQ:KALA) Stock Falls 0.9% – Time to Sell? KALA BIO, Inc. (NASDAQ: KALA - Get Free Report) shares fell 0.9% during mid-day trading on Friday. The stock traded as low as $0.2860 and last traded at $0.2940. Approximately 285,090 shares traded…
newsfilecorp.com KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone…
globenewswire.com Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channel Agreement would…
defenseworld.net KALA BIO, Inc. (NASDAQ:KALA) Given Consensus Recommendation of “Reduce” by Brokerages Shares of KALA BIO, Inc. (NASDAQ: KALA - Get Free Report) have received a consensus rating of "Reduce" from the five ratings firms that are currently covering the firm, MarketBeat.com reports. One…
globenewswire.com KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team Founder of The LSM Group to support KALA's growth across its existing business and potential acquisitions Founder of The LSM Group to support KALA's growth across its existing business and potential…
globenewswire.com Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic Testing Program Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's…
globenewswire.com Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program ARLINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek"), a CLIA-registered precision health and clinical genomics company, today…
defenseworld.net KALA BIO (KALA) Expected to Post Earnings on Thursday KALA BIO (NASDAQ: KALA - Get Free Report) is anticipated to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect KALA BIO to post earnings of ($6.00) per share…
globenewswire.com KALA BIO Announces Reverse Stock Split ARLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA BIO” or the “Company”), today announced that it intends to effect a reverse stock split of its common stock,…
globenewswire.com Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “Company”) today celebrated the landmark Executive Order signed by U.S. President Donald J.
defenseworld.net KALA BIO (NASDAQ:KALA) vs. Celularity (NASDAQ:CELU) Financial Survey Celularity (NASDAQ: CELU - Get Free Report) and KALA BIO (NASDAQ: KALA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses…
globenewswire.com Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities Engagement will assess KALA's clinical assets, development options, and AI-enabled analytical opportunities, including the MSC Secretome platform Engagement will assess KALA's clinical assets,…
globenewswire.com KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live Next-Generation Agentic AI Platform Achieves Live Enterprise Deployment, Delivering Secure, Scalable, Autonomous Research Solutions to Global Biotechnology and Pharmaceutical Organizations…
benzinga.com EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch The company confirmed that BIRA is now live in client-controlled environments, marking its entry into revenue-generating AI infrastructure.
defenseworld.net KALA BIO, Inc. (NASDAQ:KALA) Receives Consensus Rating of “Hold” from Analysts KALA BIO, Inc. (NASDAQ: KALA - Get Free Report) has been given a consensus recommendation of "Hold" by the six brokerages that are covering the firm, MarketBeat.com reports. One equities research…
globenewswire.com Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry TORONTO…
newsfilecorp.com Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry…
